TW201740918A - Skin external agent for improving skin wrinkle comprising an extract of fermented wheat germ - Google Patents

Abstract

The present disclosure relates to an external application composition for preventing, improving, or treating skin wrinkles, comprising the compound of Formula 1 of the present disclosure, or a fermentation product of wheat germ or an extract thereof as an active ingredient.

Description

Skin external preparation containing fermented wheat germ extract for improving skin wrinkles

The present disclosure relates to an external application composition of an extract containing a wheat germ fermentation product for improving skin wrinkles as an active ingredient.

In summary, skin wrinkles are known to be caused by various factors such as moisture content of the skin, collagen content, and immunity to the external environment. Among them, collagen is known as the most important form of skin wrinkles. factor.

Collagen is primarily present in the dermal layer of the skin and supports the skin by ingesting most of the extracellular matrix (ie, from about 70% to 80% of the total dry weight of the entire skin). However, wrinkles are formed by, for example, reduction of collagen synthesis due to intrinsic factors such as natural aging cell activity, and acceleration of collagen breakdown by external factors such as pressure increase due to harmful environmental conditions, and destruction of the skin matrix by sunlight. . Therefore, in order to find the active ingredients that can prevent and improve the above phenomena, many studies are underway.

Elastin in human neutrophil granules Enzyme is an enzyme that decomposes elastin. Elastin is a matrix protein that is important for maintaining skin elasticity in the dermis. It also has the activity of decomposing collagen. If elastase is properly expressed and activated, it can participate in the recovery of skin wounds and the like; however, when elastase is overexpressed or overactivated, it will decompose elastin, resulting in loss of skin elasticity. Therefore, elastase inhibitors exhibit an effect of improving skin wrinkles; ursolic acid and the like are used as elastase inhibitors.

At the same time, research has been carried out not only on natural products, such as skin external application compositions for improving skin wrinkles, such as extracts containing Anthriscus sylvestris Hoffmann or pets ( Petrselinum sativum Miller ) (Korean Patent Case) No.0507292), skin external application composition for improving wrinkles, including natural extracts such as Rheum coreanum Nakai. , Ampelopsis radix , and Santalum album (Korean Patent Case) No. 1220903) and a skin external application composition containing scleroglucan (Korean Patent Application Publication No. 2010-0043923); and also for a synthetic polymer, for example, comprising a polyurethane and an acrylic polymer The film forms a skin external preparation composition of an aqueous dispersion in which a polymer is dispersed in water (Korean Patent No. 1101363) and the like. However, skin external preparations derived from natural products having satisfactory effects of improving stability and skin wrinkles have not been developed.

In this case, the present inventors have made many efforts to develop a skin external application composition having an excellent wrinkle-reducing effect by utilizing the fermentation of natural materials, and as a result, it was found that the extract of wheat germ fermentation product and 2,6- Dimethoxybenzoquinone (2,6-DMBQ) inhibits collagen and elastic eggs White decomposition, while exhibiting excellent safety, can increase collagen biosynthesis, and it is confirmed that its application to the skin can significantly improve skin wrinkles (especially eye wrinkles), thereby completing the present disclosure.

The purpose of the present disclosure is to provide a cosmetic composition for preventing or ameliorating skin wrinkles comprising a compound of the following formula 1, or a wheat germ fermentation product or an extract thereof:

Another object of the present disclosure is to provide a pharmaceutical composition for preventing or treating skin wrinkles comprising a compound of the above formula 1, or a wheat germ fermentation product or an extract thereof.

Still another object of the present disclosure is to provide a quasi-drug composition for skin wrinkles comprising a compound of the above formula 1, or a wheat germ fermented product or an extract thereof.

Still another object of the present disclosure is to provide a method for preventing, ameliorating, or treating skin wrinkles, which comprises administering a compound of formula 1 or a wheat germ fermented product or an extract thereof, or the present disclosure, to a subject in need thereof Composition.

In order to achieve the above object, an aspect of the present invention provides a cosmetic composition for preventing or ameliorating skin wrinkles, which comprises a compound represented by the following formula 1, or a wheat germ fermentation product or an extract thereof.

The compound which can be contained as an active ingredient in the cosmetic composition of the present disclosure can be represented by the following formula 1.

The compound of the above formula 1 is named as a compound of 2,6-dimethoxybenzoquinone (2,6-DMBQ), which may be chemically or biosynthetically, or may be purchased from commercially available or used. It is isolated from a natural product (for example, a plant or the like) which is known to contain the compound, but the method of obtaining the compound is not particularly limited thereto. In the present disclosure, it was confirmed that the compound represented by Formula 1 contained in the wheat germ fermentation product or its extract has the effect of preventing or improving skin wrinkles.

The term "wheat germ" as used herein refers to the germ of wheat seeds; it is a germ with sufficient nutrients for wheat grains, which is removed during the milling process of treating whole wheat into flour, accounting for about 2% to about 3 of whole wheat kernels. %. Wheat germ is known to be rich in vitamin E (tocopherol), which is known to be an antioxidant vitamin. According to recent research, it is known that natural materials extracted from fermented wheat germ have restored immune function in humans. The effect. However, the effect of wheat germ on improving skin wrinkles has not yet been Learned.

The wheat germ of the present disclosure may contain a dried product, a concentrate, or a mixture thereof, but is not limited thereto.

As used herein, the term "fermentation" generally refers to any activity or process that utilizes the enzymatic or metabolic decomposition (digestion) of an organic material by a microorganism.

The term "wheat germ fermentation product" as used herein refers to a product obtained by the enzymatic or metabolic decomposition of a microorganism in a wheat germ.

The wheat germ fermentation product of the present disclosure may comprise a compound of formula 1.

In the present disclosure, the wheat germ fermented product can be referred to by culturing the microorganism after inoculating the wheat germ or the medium containing the same. Specifically, the microorganism may be at least one selected from the group consisting of yeast, lactic acid bacteria, bacteria, and fungi.

The yeast may be Saccharomyces cerevisiae , S. ellipsoideus , S. coreanus , S. carlsbergensis , S. pastorianus . , lactic yeast (S.lactis), Lu's yeast (S.rouxii), Schizosaccharomyces pombe (Schizosaccharomyces pombe), engaging moromi yeast (Zygosaccharomyces major), abnormal Hanson yeast (Hansenula anomala), Brussels Brettanomyces bruxellensis , B. custersianus , Dekkera anomala , Streptomyces olivochromogenes , or Streptomyces griseus ( S. griseus) However, it is not limited thereto, as long as the yeast can exhibit the effect of preventing or improving skin wrinkles for the purpose of the present disclosure. For example, the yeast can be Saccharomyces cerevisiae.

Lactic acid bacteria may be Bifidobacterium (Bifidobacterium), Lactobacillus (Lactobacillus), the genus Lactococcus lactis (Lactococcus), Pediococcus (Pediococcus), Streptococcus (Streptococcus), Lactococcus or white beads (Leuconostoc) like the genus The microorganism, but is not limited thereto, as long as the bacterium exhibits the effect of preventing or improving skin wrinkles for the purpose of the present disclosure. For example, the bacterium may be a Bifidobacterium tarda (B.bifidum), Bifidobacterium breve (B. breve), Bifidobacterium longum (B. longum), Bifidobacterium animalis (B.animalis), lactic acid bifidobacteria (B.lactis), Lactobacillus acidophilus (L. acidophilus), Lactobacillus casein (L.casei), Lactobacillus gasseri (L.gasseri), Lactobacillus Daibai Shi (L.delbrueckii spp. ), Lactobacillus bulgaricus (L.bulgaricus), Switzerland Lactobacillus (L.helveticus), Po fermentation lactic acid bacteria (L.fermentum), Vice Lactobacillus casei (L.paracasei), germ Lactobacillus (L.plantarum), Los Germany Lactobacillus (L.reuteri), Lactobacillus rhamnosus (L.rhamnosus), salivary lactobacilli (L.salivarius), lactic acid Lactobacillus (L.lactis), beer small cocci (P.cerevisiae), lactic small cocci (P.acidilactici), Streptococcus lactis (S.lactis), Streptococcus thermophilus (S.thermophiles), Streptococcus cheese (S.cremoris), or intestinal membrane white candidiasis (L.mesenteroides). In the present disclosure, Lactobacillus and Lactobacillus can be used in the same sense.

In addition, the fungi used in the fermentation may include mushrooms, but are not limited thereto, and the mushrooms may include, for example, Lentinus edodes , Pleurotus ostreatus , Enokitake , Matsutake . ), Agaricus bisporus , Auricularia auricula-judae , Hericium erinaceum , Ganoderma japonicum , or Phellinus linteus , but not limited to this, as long as the mushroom It can be used for the purpose of preventing or improving skin wrinkles for the purpose of the present disclosure.

The microbial inoculum amount, the culture temperature, the culture humidity, and the culture time for preparing the wheat germ fermentation product of the present disclosure can be appropriately selected by those having ordinary knowledge in the art to take into consideration the type of microorganism used in the fermentation. Non-limiting examples of the culture of the present disclosure may be carried out at 20 ° C to 40 ° C for 12 hours to 60 hours. Specifically, the culture of the present disclosure can be carried out at a temperature of 25 ° C to 35 ° C, 28 ° C to 32 ° C, or at 30 ° C and/or for 12 hours to 50 hours, 20 hours to 50 hours, 30 hours to 50 hours, 35 hours to 45 hours, 38 hours to 42 hours, or 40 hours.

As used herein, the term "extract of wheat germ fermentation product" refers to a material obtained by removing microorganisms from a fermentation product.

The removal in the present disclosure may include any method as long as the method can remove microorganisms (for example, yeast bodies) contained in the microorganism fermentation product. Specifically, the wheat germ fermentation product of the present disclosure may be a supernatant obtained by centrifuging the wheat germ fermentation product of the present disclosure. More specifically, the centrifugation may be performed at 6,000 rpm to 10,000 rpm, 7,000 rpm to 90,000 rpm, 7,500 rpm to 8,500 rpm, 7,800 rpm to 8,200 rpm, or 8,000 rpm for 5 minutes to 120 minutes, 5 minutes to 90 minutes, 5 minutes. Up to 60 minutes, 5 minutes to 40 minutes, 5 minutes to 30 minutes, 10 minutes Clock to 120 minutes, 10 minutes to 90 minutes, 10 minutes to 60 minutes, 10 minutes to 40 minutes, 10 minutes to 30 minutes, 15 minutes to 120 minutes, 15 minutes to 90 minutes, 15 minutes to 60 minutes, 15 minutes to 40 minutes, 15 minutes to 30 minutes, 15 minutes to 25 minutes, or 20 minutes.

The wheat germ fermentation product of the present disclosure may comprise the compound of the formula 1 of the present disclosure, but is not particularly limited thereto.

The extract of the wheat germ fermentation product disclosed herein comprises, for example, the formation of the wheat germ fermentation product itself, a dilution thereof, a concentrate thereof, a dried product thereof, a crude purified product thereof, a purified product thereof, or a mixture thereof. Extracts of various formulations. In particular, the extract of the wheat germ fermentation product disclosed herein may be a dried product, more specifically a lyophilized product.

Further, the extract of the wheat germ fermentation product of the present disclosure can be obtained from the wheat germ fermentation product by any method as long as the extract has the effect of preventing, improving, or treating skin wrinkles. Non-limiting examples of the method of obtaining the extract may include cold-precipitation in which a wheat germ fermentation product is immersed in a solvent and then subjected to room temperature extraction at 10 ° C to 25 ° C; thermal extraction using heating at 40 ° C to 100 ° C Method; a vibrating treatment extraction method using a sound vibration treatment; a reflux extraction method using a reflux condenser. These methods may be carried out singly or in combination of two or more.

The kind of the extraction solvent used in the extraction of the present disclosure is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent of the present disclosure may include a group selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform, and dichloromethane. Solvent. Specifically, the extraction solvent of the present disclosure may be hot water.

The extracts of the present disclosure may include fractions thereof. As used herein, the term "fractionation" refers to the product obtained by fractional distillation from the results of a single component or mixture of components comprising a mixture of ingredients.

The fractionation method for obtaining the fractionated product of the present disclosure is not particularly limited, and any method conventionally used in the art can be used. Examples of the fractionation method may include solvent fractionation using fractional distillation using various solvents; ultrafiltration fractionation by fractionation through an ultrafiltration membrane having a constant molecular cutoff; various chromatographic methods (manufactured for size, charge, and hydrophobicity) Or the separation of affinity, its combination, and the like.

The fractionation solvent used to obtain the fraction of the present disclosure is not particularly limited. Only any solvent known in the art can be used. Non-limiting examples of the fractionating solvent of the present disclosure may include polar solvents such as water, alcohols, and the like; and non-polar solvents such as hexane, ethyl acetate, chloroform, dichloromethane, and the like. These solvents may be used singly or in combination of at least one.

The content of the wheat germ fermentation product or the extract thereof of the present disclosure may be from 0.001% by weight to 10% by weight based on the total weight of the composition of the present disclosure, specifically, 0.01% by weight based on the total weight of the composition of the present disclosure. Up to 7 wt%, 0.01 wt% to 5 wt%, 0.01 wt% to 3 wt%, 0.01 wt% to 2 wt%, 0.01 wt% to 1 wt%, 0.05 wt% to 10 wt%, 0.05 wt% to 7 wt%, 0.05 wt% to 5 wt%, 0.05 wt% to 3 wt%, 0.05 wt% to 2 wt%, 0.05 wt% to 1 wt%, 0.1 wt% to 10 wt%, 0.1 wt% to 7 wt%, 0.1 wt% to 5 wt%, 0.1 wt% to 3 wt% %, 0.1 wt% to 2 wt%, 0.1 wt% to 1 wt%, 0.5 wt% to 10 wt%, 0.5 wt% to 7 wt%, 0.5 Wt% to 5 wt%, 0.5 wt% to 3 wt%, 0.5 wt% to 2 wt%, 0.5 wt% to 1 wt%, 0.8 wt% to 10 wt%, 0.8 wt% to 7 wt%, 0.8 wt% to 5 wt%, 0.8 wt% % to 3 wt%, 0.8 wt% to 2 wt%, 0.8 wt% to 1 wt%, or 1 wt%.

In the composition of the present disclosure, the content of the wheat germ fermentation product or the extract thereof may be from 0.1 μg/mL to 200 μg/mL. Specifically, in the composition of the present disclosure, the content of the wheat germ fermentation product or the extract thereof may be from 0.1 μg/mL to 150 μg/mL, from 0.1 μg/mL to 100 μg/mL, from 0.1 μg/mL to 70 μg/mL, 0.1 μg/mL to 50 μg/mL, 0.5 μg/mL to 200 μg/mL, 0.5 μg/mL to 150 μg/mL, 0.5 μg/mL to 100 μg/mL, 0.5 μg/mL to 70 μg/mL, 0.5 Gg/mL to 50 μg/mL, 0.8 μg/mL to 200 μg/mL, 0.8 μg/mL to 150 μg/mL, 0.8 μg/mL to 100 μg/mL, 0.8 μg/mL to 70 μg/mL, 0.8 μg/mL to 50 μg /mL, 1 μg/mL to 200 μg/mL, 1 μg/mL to 150 μg/mL, 1 μg/mL to 100 μg/mL, 1 μg/mL to 70 μg/mL, 1 μg/mL to 50 μg/mL, 5 μg/mL to 200 μg/mL 5 μg/mL to 150 μg/mL, 1.5 μg/mL to 100 μg/mL, 5 μg/mL to 70 μg/mL, 5 μg/mL to 50 μg/mL, 8 μg/mL to 200 μg/mL, 8 μg/mL to 150 μg/mL, 8 μg/mL to 100 μg/mL, 8 μg/mL to 70 μg/mL, 8 μg/mL to 50 μg/mL, 10 μg/mL to 200 μg/mL, 10 μg/mL to 150 μg/mL, 10 μg/mL to 100 μg/mL, 10 μg/ mL to 70 μg/mL, or 10 μg/mL to 50 μg/mL.

In addition, the compound of the formula 1 may be used in an amount of 0.00001% by weight to 0.1% by weight based on the total weight of the composition of the present disclosure. The content may be 0.0001 wt% to 0.07 wt%, 0.0001 wt% to 0.05 wt%, 0.0001 wt% to 0.3 wt%, 0.0001 wt% to 0.02 wt%, 0.0001 wt% to 0.01 wt%, 0.0005 wt%. To 0.1 wt%, 0.0005 wt% to 0.07 wt%, 0.0005 wt% to 0.05 wt%, 0.0005 wt% to 0.03 wt%, 0.0005 wt% to 0.02 wt%, 0.0005 wt% to 0.01 wt%, 0.001 wt% to 0 .1 wt%, 0.001 wt% to 0.07 wt%, 0.001 wt% to 0.05 wt%, 0.001 wt% to 0.03 wt%, 0.001 wt% to 0.02 wt%, 0.001 wt% to 0.01 wt%, 0.005 wt% to 0.1 wt. %, 0.005 wt% to 0.07 wt%, 0.005 wt% to 0.05 wt%, 0.005 wt% to 0.03 wt%, 0.005 wt% to 0.02 wt%, 0.005 wt% to 0.01 wt%, or 0.007 wt%.

Further, in the composition of the present disclosure, the compound of the present formula 1 may be contained in an amount of from 0.1 ng/mL to 1250 ng/mL. Specifically, in the composition of the present disclosure, the content of the fermentation product or the extract thereof may be from 0.1 ng/mL to 1000 ng/mL, from 0.1 ng/mL to 500 ng/mL, from 0.1 ng/mL to 200 ng/ mL, 0.1 ng/mL to 120 ng/mL, 0.1 ng/mL to 90 ng/mL, 0.1 ng/mL to 60 ng/mL, 0.1 ng/mL to 30 ng/mL, 1 ng/mL to 1250 ng/mL, 1 ng/mL to 1000 ng/mL, 1 ng/mL to 500 ng/mL, 1 ng/mL to 200 ng/mL, 1 ng/mL to 120 ng/mL, 1 ng/mL to 90 ng/mL, 1 ng/mL to 60 ng/mL, 1 ng/mL to 30 ng/ mL1, 1 ng/mL to 1250 ng/mL, 1 ng/mL to 1000 ng/mL, 1 ng/mL to 500 ng/mL, 1 ng/mL to 200 ng/mL, 1 ng/mL to 120 ng/mL, 1 ng/mL to 90 ng/mL 1ng/mL to 60ng/mL, 1ng/mL to 30ng/mL, 5ng/mL to 1250ng/mL, 5ng/mL to 1000ng/mL, 5ng/mL to 500ng/mL, 5ng/mL to 200ng/mL, 5ng /mL Up to 120 ng/mL, 5 ng/mL to 90 ng/mL, 5 ng/mL to 60 ng/mL, 5 ng/mL to 30 ng/mL, 10 ng/mL to 1250 ng/mL, 10 ng/mL to 1000 ng/mL, 10 ng/mL to 500 ng /mL, 10 ng/mL to 200 ng/mL, 10 ng/mL to 120 ng/mL, 10 ng/mL to 90 ng/mL, 10 ng/mL to 60 ng/mL, 10 ng/mL to 30 ng/mL, 15 ng/mL to 1250 ng/mL 15ng/mL to 1000ng/mL, 15ng/mL to 500ng/mL, 15ng/mL to 200ng/mL, 15ng/mL to 120ng/mL, 15ng/mL to 90ng/mL, 15ng/mL to 60ng/mL, 15ng /mL to 30ng/mL, 30ng/mL to 1250ng/mL, 30ng/mL to 1000ng/mL, 30ng/mL to 500ng/mL, 30ng/mL to 200ng/mL, 30ng/mL to 120ng/mL, 30ng/mL Up to 90 ng/mL, 30 ng/mL to 60 ng/mL, 60 ng/mL to 1250 ng/mL, 60 ng/mL to 1000 ng/mL, 60 ng/mL to 500 ng/mL, 60 ng/mL to 200 ng/mL, 60 ng/mL to 120 ng /mL, or 60 ng/mL to 90 ng/mL.

As used herein, the term "wrinkle" refers to a slight line formed in the skin due to skin degradation, which may be caused by a decrease in collagen, skin collagen content, and external environmental causes. The term "wrinkle" can encompass the concept of skin aging or reduced skin elasticity. The term "aging of the skin" as a whole refers to the tangible and intangible changes that occur in the skin as the aging process occurs, and may include not only any specific environmental factors that occur with each person's internal aging (ie, natural aging) over time, but also Including aging due to stress, UV, smoking, medication, etc. Photoaging, which is external aging, refers to skin damage that occurs when skin is repeatedly or exposed to sunlight UV rays for a long time, such as skin elasticity and moisture content, and wrinkles. Injury. Specifically, photoaging can be used to cause degeneration of solar elastic fibers such as carbon fiber modification or deposition, collagen fiber insulation, and the like.

The wrinkles of the present disclosure can be applied to the face, such as the eyes, the eyebrows, and the forehead, neck, etc., especially the wrinkles of the eyes.

In accordance with illustrative embodiments of the present disclosure, the compositions of the present disclosure promote collagen native synthesis, inhibit the expression of collagenase (MMP-1) and elastase activity via ultraviolet light, and inhibit and/or increase skin firmness.

As used herein, the term "prevention" refers to all of the effects of the disclosed pharmaceutical compositions which inhibit or delay the loss of skin elasticity or wrinkles.

As used herein, the term "improvement" refers to all of the effects of the disclosed pharmaceutical compositions of reducing the parameters associated with the state of wrinkles (e.g., the degree of wrinkles). In particular, in the present disclosure, the improvement may be directed to reducing wrinkle depth, increasing skin firmness, and/or reducing the number of wrinkles in a particular area.

The cosmetic composition of the present disclosure may be selected from the group consisting of a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a cleaning oil containing a surfactant, a foundation, an emulsion base, a wax base, Sprays, and packs are provided in the form of a group.

The cosmetic composition of the present disclosure further comprises a carrier.

The cosmetically acceptable carrier which can be used in the present disclosure is not particularly limited as long as the carrier does not inhibit biological activity or its characteristics, and any carrier which is conventional and cosmetically acceptable can be used. Non-limiting examples of cosmetically acceptable carriers can include saline, sterile water, buffered saline, Glucose solution, maltodextrin solution, glycerin, ethanol, and the like. These carriers may be used singly or in combination of at least two. In the present disclosure, a vector can include a non-naturally occurring carrier.

The cosmetically acceptable carrier of the present disclosure may vary depending on the formulation of the cosmetic composition.

When the formulation of the cosmetic composition of the present disclosure is in the form of a paste, a cream, or a gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, hydrazine can be used. And bentonite, cerium oxide, talc, zinc oxide, or the like as a carrier component, but the carrier component is not limited thereto.

When the formulation of the cosmetic composition of the present disclosure is in the form of a powder or a spray, lactose, talc, ceria, aluminum hydroxide, calcium citrate, polyamide powder or the like may be used as a carrier component, in particular, when When the formulation is in the form of a spray, a propellant such as chlorofluorocarbon, propane/butane, or dimethyl ether may be additionally included, but the carrier component is not limited thereto.

When the formulation of the cosmetic composition of the present disclosure is in the form of a solution or an emulsion, a solvent, a solubilizing agent, or an emulsifier or the like may be used as a carrier component. For example, water, ethanol, isopropanol or diethyl carbonate may be used. Ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol oil, especially cottonseed oil, peanut oil, wheat germ oil, olive oil, castor oil and sesame oil, fatty acid glycerides, polyethylene A fatty acid ester of a glycol or sorbitan, but the carrier component is not limited thereto.

When the formulation of the cosmetic composition of the present disclosure is in the form of a suspension, a liquid diluent such as water, ethanol, or propylene glycol may be used; Suspending agents, such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; microcrystalline cellulose; aluminum metahydroxide; bentonite; agar; The gum is used as a carrier component, but the carrier component is not limited thereto.

When the formulation of the cosmetic composition of the present disclosure is in the form of a soap, an alkali metal salt of a fatty acid, a fatty acid-protein hydrolysate, a isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerin, or a sugar can be used. The class or the like serves as a carrier component, but the carrier component is not limited thereto.

When the formulation of the cosmetic composition of the present disclosure is in the form of a film, all of the film may be included, for example, a release film containing polyvinyl alcohol or the like; wherein the general emulsion type cosmetic contains, for example, kaolin, talc, zinc oxide, or a washing film of a pigment such as titanium oxide; and a mask sheet, but the film is not particularly limited thereto.

The composition may further contain a component which is conventionally contained as an external preparation for skin, such as water, a surfactant, a wetting agent, a lower alcohol, a chelate, a bactericide, an antioxidant, a pigment, a fragrance, and the like.

In order to achieve the object of the present disclosure, another aspect of the present disclosure provides a pharmaceutical composition for preventing or treating skin wrinkles comprising a compound of the following formula 1, or a wheat germ fermentation product or an extract thereof.

Regarding the pharmaceutical composition of the present disclosure, all wheat germs Buds, wheat germ fermented products, extracts of wheat germ fermented products, skin wrinkles, and prevention are all applicable.

As used herein, the term "treating" refers to the various effects of the composition to ameliorate or help to alter the symptoms of wrinkles in the skin. Specifically, it may mean reducing the depth of wrinkles, increasing the firmness of the skin, reducing the number of wrinkles, and / or remove wrinkles.

In the present disclosure, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.

The term "pharmaceutically acceptable carrier" as used herein refers to a carrier or diluent which does not cause significant irritation to the organism, nor does it inhibit the activity or properties of the disclosed pharmaceutical compositions for preventing or treating wrinkles. Examples of the pharmaceutically acceptable carrier to be prepared in a liquid solution, suitable for sterilization and biocompatibility in the composition may include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution. , maltodextrin solution, glycerin, and ethanol, and at least one of these components may be used in combination. Other conventional additives such as antioxidants, buffered saline, bacteriostatic agents and the like may be added as needed.

In the present disclosure, a pharmaceutically acceptable carrier can include a carrier that is not naturally occurring.

The pharmaceutical compositions of the present disclosure may be administered in a pharmaceutically effective amount in a single dose or in multiple doses.

The term "pharmaceutically effective amount" as used herein means an amount sufficient to prevent or treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dosage may be based on the severity of the disease, the activity of the drug, Factors such as patient weight, health status, sex, drug sensitivity, time of administration of the disclosed compositions, route of administration and dissolution rate, duration of treatment, and the like, including factors in combination with the disclosed compositions or drugs to be used in combination And other factors known in the medical field are determined.

As used herein, the term "giving" refers to the introduction of a particular material to a subject in an appropriate manner, and the compositions of the present disclosure can be administered via any of the usual routes, as long as the composition can be used to reach a target tissue in vivo. The composition of the present disclosure can be administered orally or parenterally, but is not particularly limited thereto. Specifically, the composition may be administered parenterally, and more specifically, the composition may be administered by a method of applying the composition to the skin (ie, application of the skin). In particular, the administration of the present disclosure can be carried out 1 to 4 times, 2 to 3 times, or 2 times a day. Furthermore, the administration of the present disclosure can be carried out for at least 4 weeks, at least 8 weeks, or for a period of 4 weeks to 12 weeks, or for a period of 8 weeks to 12 weeks.

In order to achieve the above object, yet another aspect of the present disclosure provides a quasi-drug composition for preventing or ameliorating skin wrinkles comprising the compound of the present formula 1, or a wheat germ fermentation product or an extract thereof.

Regarding the quasi-drug composition of the present disclosure, all of the above-mentioned compounds of the present disclosure formula 1, wheat germ, wheat germ fermentation product, or wheat germ fermentation product extract, skin wrinkles, prevention, and improvement are applicable thereto.

As used herein, the term "quasi-drug" refers to a product that has a mild effect compared to a medical drug used in the diagnosis, cure, amelioration, amelioration, treatment, or prevention of a human or animal disease product. For example, according to the Korean Pharmaceutical Law, "quasi-drugs" include products other than drugs. In addition, products for treating or preventing humans and animals and having a mitigating effect on the human body or not directly acting thereon.

The quasi-drug composition of the present disclosure may be prepared in the form of a group selected from the group consisting of body cleansers, foams, soaps, patches, ointments, creams, lotions, perfumes, and sprays, but is not limited thereto.

An extract of the compound of the formula 1, the wheat germ fermented product, or the wheat germ fermented product of the present disclosure when using the extract of the compound of the disclosure formula 1, the wheat germ fermentation product or the wheat germ fermentation product as an additive to the quasi-drug It may be added as such or in combination with other quasi-drug or quasi-drug ingredients, and may be suitably used according to a conventional method.

In order to achieve the above object, yet another aspect of the present disclosure provides a method for preventing, ameliorating, or treating skin wrinkles, which comprises administering a compound of the present formula, a wheat germ fermentation product or an extract to a subject in need thereof. Or the composition of the present disclosure.

Regarding the method for preventing, ameliorating, or treating skin wrinkles of the present disclosure, all of the above compounds of the present formula 1, wheat germ, wheat germ fermented product, extract of wheat germ fermented product, skin wrinkles, prevention, improvement, And treatment is applicable to it.

The composition of the present disclosure is not toxic, and also exhibits effects of promoting collagen synthesis, inhibiting the expression of collagenase and elastase via ultraviolet rays, and reducing skin firmness and skin wrinkle depth, and thus can be used for prevention, improvement, or treatment. Skin wrinkles.

1 is a graph showing the results of conversion of 2,6-DMBQ content in a wheat germ fermentation product extract according to a specific example of the present disclosure, wherein a calibration curve is drawn using the disclosed compound 2,6-DMBQ, and the calibration curve is used to convert Crest area.

Fig. 2 is a graph showing the results of cytotoxicity test on NHDF cells with respect to wheat germ extract product extract (CJ) according to a specific example of the present disclosure.

Figure 3 shows the results of 2,6-DMBQ assay for cytotoxicity of human skin fibroblasts.

Figures 4a and 4b show graphs illustrating the synthesis of type 1 collagen precursors of wheat germ extract product extracts (Fig. 4a) and 2,6-DMBQ (Fig. 4b) according to specific examples of the present disclosure. .

Figures 5a and 5b show the inhibition of MMP-1 production induced by UV irradiation in relation to wheat germ extract product extract (Fig. 5a) and 2,6-DMBQ (Fig. 5b) according to specific examples of the present disclosure. Figure.

Fig. 6 is a graph showing the elastase inhibitory activity of the wheat germ extract product extract according to the specific examples exemplified in the present disclosure.

Figure 7 shows an explanatory diagram explaining the wrinkle parameters R1 and R3 in the case of measuring wrinkles around the eyes.

Figures 8a to 8f show comparison results between wheat germ extract product extract (CJD cream) and negative control product (control cream) product according to specific examples of the present disclosure, wherein Figure 8a shows the time point according to the time point The pattern of changes in skin wrinkles around the eyes after the use of these products; Figure 8b shows a graph showing the change in the percentage of wrinkles around the eyes according to the time of use of the product; Figure 8c shows an image showing the change in wrinkles around the eyes of the subject according to the use of the product. Figure 8d shows a graph showing the skin firmness change of the skin according to the time point; Figure 8e shows a graph showing the percentage change of the skin firmness of the skin according to the time point of use of the product; and Figure 8f shows the basis according to the product The image of the subject's skin tightness changes.

Figures 9a to 9f show the results of comparisons between wheat germ extract product extract (CJD cream) and positive control product (Adenine-containing ADE cream) products according to specific examples of the present disclosure, wherein Figure 9a shows Explain the change pattern of skin wrinkles around the eyes according to the time point of product use; Figure 9b shows the graph of the percentage change of wrinkles around the eyes according to the time point of product use; Figure 9c shows the image of the change of wrinkles around the eyes of the object according to the use of the product; Figure 9d shows a graph showing skin firmness changes according to the time point; Figure 9e shows a graph showing the percentage change of skin firmness according to the time point of product use; and Figure 9f shows the use of the object according to the product. An image of skin tightness changes.

Hereinafter, the present disclosure will be described in more detail with reference to the following examples. However, the examples are for illustrative purposes only, and the invention is not intended to be limited by the embodiments.

Preparation Example 1: Preparation of Wheat Germ Fermentation Product Extract

Wheat germ (50 g, CJ Cheiljedang Corp., Korea) and water (500 g) were added to the flask, thoroughly mixed, and sterilized at 121 ° C for 15 minutes, and cooled. Then, dry yeast (Baker's yeast, Saccharomyces cerevisiae, Angel yeast, 5%, 2.5 g) is inoculated according to the weight of the wheat germ. The supernatant was incubated at 30 ° C for 40 hours and centrifuged at 8000 rpm for 20 minutes to recover the supernatant. The supernatant was recovered via freeze-drying to prepare an extract of the wheat sprout fermentation product.

In this embodiment, the extract of the wheat germ fermentation product is designated "CJ".

Preparation Example 2: Composition Analysis of Extracts from Wheat Germ Fermentation Products

The results of high performance liquid chromatography (HPLC) analysis of the extract components of wheat germ fermentation products have confirmed that it contains 2,6-DMBQ in an amount of 700 ppm based on the lyophilized product of the wheat germ fermentation product extract.

After diluting the commercially available 2,6-DMBQ (Sigma-Aldrich) according to the concentration using chloroform, a calibration curve was drawn using 2,6-DMBQ (Sigma-Aldrich), and the wheat germ fermentation product was calculated by conversion using the calibration curve. The peak area of DMBQ in the extract was calculated to calculate the DMBQ content (Fig. 1).

The 2,6-DMBQ system used in the following experimental examples and examples was purchased from Sigma-Aldrich.

Experimental Example 1: Analysis of cell viability

Cell viability analysis was performed on NHDF cells against the wheat germ fermentation product extract (CJ) of Preparation Example 1. Specifically, NHDF cells were equally divided into 96-well culture dishes at a concentration of 6 × 10 ³ cells/well, and added to 0.1% insulin, 0.1% rhFGF, 0.1% gentamicin, The fibroblast basal medium (FBM, Lonza, CC-3131) of 2% FBS was cultured in an incubator (5% CO ₂ , 37 ° C) for 24 hours. After the culture, the cells were maintained starved for 12 hours, and then the wheat germ fermentation product extract (experimental group) according to the preparation example 1 and the FBM medium (control group) containing no supplement were added thereto, and culture was carried out. hour. Next, in order to measure the cell viability, the water-soluble tetrazolium salt-1 (WST-1, Roche) reaction solution was diluted 1:10 in the FBM medium containing no supplement, and the diluted reaction solution was loaded. The cells were filled in each tank (100 μL/well), and after reacting for 1 hour, the absorbance at 450 nm was measured.

Then, the relative cell viability of NHDF cells treated with the wheat germ extract product extract (CJ) of Preparation Example 1 was directed to NHDF cells treated only with the FBM medium without the sample (denoted as "control group"). Percentage (%) is indicated.

As a result, it was confirmed that specific cytotoxicity was not observed in the sample treatment at a concentration of 200 μg/mL or less (Fig. 2). Therefore, in the subsequent in vitro experiment, the concentration of the sample was set at 50 μg/mL or less.

In addition, cell viability analysis was performed in human skin fibroblasts against 2,6-DMBQ (Sigma-Aldrich). Specifically, HDF cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin to a concentration of 6 × 10 ⁵ cells/dish. These cell lines were cultured in a culture vessel (5% CO ₂ , 37 ° C) using a cell culture dish (100 mm), and cells reaching a fullness were maintained by subculture using trypsin-EDTA.

Then, HDF cells at a concentration of 2×10 ³ cells/well were cultured in a 96-well cell culture dish using DMEM (thermo) medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, and Processed with 2,6-DMBQ. For the treatment of 2,6-DMBQ, 2,6-DMBQ was dissolved in water, diluted to a ratio of 1:2 according to the concentration to prepare a stock solution, and diluted in DMEM (serum-free, 1% P/S) medium to Final concentrations (0.3125 μg/mL, 0.625 μg/mL, and 1.25 μg/mL) were incubated for 48 hours. After the completion of the culture, the medium was replaced with DMEM (serum-free, 1% P/S) medium containing EZ-CYTOX (EZ-1000, Daeil Lab Service, Korea), and the cell absorbance at 450 nm was measured using a microplate reader. To get its cell survival rate.

As a result, it was confirmed that no toxicity was observed at a concentration of 1.25 μg/mL or less (Fig. 3).

Experimental Example 2: Evaluation of wrinkle improvement effect

2-1: Experiment to promote the primary synthesis of type 1 collagen

NHDF cells were aliquoted into a 48-well culture dish at a concentration of 1 × 10 ⁴ cells/well, and cultured for 24 hours in the same FBM medium as in Experimental Example 1. Next, the medium was removed, and the sample of Preparation Example 1 and 2,6-DMBQ were used according to the concentration (wheat germ extract product extract: 1 μg/mL, 10 μg/mL) while maintaining the cells in a starved state for 24 hours. 50 μg/mL; and 2,6-DMBQ: 15 ng/mL, 30 ng/mL, 60 ng/mL, and 120 ng/mL were each diluted in cell-treated FBM (without supplement) and cultured for 24 hours. Then, the culture medium of the cultured cells was recovered, and the collagen amount was measured using the EIA kit (TAKARA, MK101) of the first type collagenogen carbonyl end peptide (PIP). At the same time, the cells attached to the bottom were washed with PBS, dissolved in 1 N NaOH, and the total amount of protein was measured to calculate the amount of collagen synthesis per unit specific protein.

As a result, it was confirmed that the extract of the wheat germ fermentation product increased the production of collagenogen in a concentration-dependent manner (Fig. 4a). In addition, in the case of 2,6-DMBQ, it promotes collagenogen in a statistically significant amount in the concentration range of 15 ng/mL to 120 ng/mL, and is in a concentration from 15 ng/mL to 30 ng/mL. The dependent mode exhibited an effect, and when it was treated at a concentration of 30 ng/mL, the collagen protein was promoted at the highest level of 188.53±9.23%, thus confirming its excellent effect of promoting collagen expression, similar to the positive control group (Table 2, Figure 4b, paired t-test: *p<0.05, **p<0.01, ***p<0.001).

2-2: Experiment to inhibit the expression of collagenase (MMP-1)

In various mechanisms for forming wrinkles, the effect of the sample on the improvement of wrinkles was evaluated by measuring the amount of matrix metalloproteinase-1 (MMP-1) of collagen degrading enzyme expressed by UV irradiation by ELISA immunoassay.

Specifically, NHDF cells were aliquoted into a 24-well culture dish at a concentration of 2 × 10 ⁴ cells/well, and cultured in the same medium as Experimental Example 1 for 24 hours. After the medium was removed at 24 hours, the cells were washed with DPBS, DPBS (200 μL) was added thereto, and the cells were irradiated with UV-B (40 mJ/cm ² ). Next, the wheat germ fermentation product extract (CJ) of Preparation Example 1 having the same concentration as in Experimental Example 2-1 was each treated into cells, and the cells were cultured for 24 hours. Then, the culture solution was collected and the amount of MMP-1 was measured using a human total MMP-1 ELISA kit (R&D system, DY901). The measured amount of MMP-1 was calibrated based on the total protein amount. Regarding the 2,6-DMBQ treatment, the amount of MMP-1 was measured in the same manner except that the UV-B irradiation was carried out at 15 mJ/cm ² and retinyl acid was used as a positive control group.

As a result, when the control group (+) showing increased MMP-1 expression due to UVB irradiation was treated with wheat germ fermentation product extract (CJ), the amount of MMP-1 was significantly reduced in a concentration-dependent manner (Fig. 5a) ).

In addition, when treated with 2,6-DMBQ, it showed a significant degree of inhibitory effect on MMP-1 from 15 ng/mL to 120 ng/mL, and the effect was shown to be concentration-dependent, thus confirming that compared with the negative control group, Treatment at 120 ng/mL inhibited performance by up to 68% (Tables 3 and 5b).

2-3: Experiment of elastase inhibition

In order to confirm the inhibitory effect of wheat germ extract product extract and 2,6-DMBQ on elastase activity, it was evaluated for their elastase and its substrate N-amber-based-(Ala)3-p-nitroanilide (N- The degree of inhibition of the reaction between STANA). First, 0.2 M Tris-HCl (pH 8.0) containing 0.1% Triton X-100 was added to NHDF cells (i.e., dermal fibroblasts), and the cells were homogenized using an ultrasonic processor. The resultant was centrifuged at 3,000 rpm for 20 minutes, and the supernatant was used as a sample for determining elastase activity.

The above sample (200 g/mL), 0.2 M Tris-HCl buffer solution, and wheat germ fermentation product extract (CJ) of Preparation Example 1 were mixed according to the concentration, and 50 mM N-STANA was added thereto. This mixture was incubated at 37 ° C and the absorbance at 405 nm was measured. Then, the degree of inhibition of elastase activity was calculated as compared with a negative control group (expressed as "-") which was not treated with wheat germ extract product extract. Aminone phosphate (10 mM, expressed as "+") known as an elastase inhibitor was used as a positive control group.

As a result, it was confirmed that the wheat germ extract product extract (50 μg/mL) inhibited about 62% of elastase activity compared to the negative control group, while exhibiting an inhibitory effect equivalent to that of the positive control group (Fig. 6).

Example 1: Preparation of a cosmetic cream containing wheat germ extract product extract

1-1. Preparation of cosmetic cream

As a composition (% by weight) disclosed in Table 4 below, a cosmetic cream containing the extract of wheat germ extract of Preparation Example 1 as an active ingredient was prepared according to a conventional method.

1-2. Clinical evaluation of the effect of cosmetic cream wrinkle improvement

1-2-1: Experimental Outline

Via the negative control group (the above table 3 composition contains the same amount of distilled water instead of the wheat germ extract product extract cream, the following "control cream") and the positive control group [including the same amount because of The cosmetic cream prepared in Example 1-1 is compared with the raw material adenosine (0.04%), which is a wrinkle-improving function, and the cream of the wheat germ extract product extract, hereinafter "ADE Cream". ("CJD Cream" below) was evaluated clinically for the effect of wrinkle improvement. 20 adult women aged 30 to 55 years old who formed wrinkles at the eyes [the gross visual assessment of the standard operating procedures (SOP) of the Kyung Hee University of Korea, Grade 3 or above].

First, the sites of "control cream" and "ADE cream" were administered using pool randomization and allowed to use for 12 weeks. Then, before the use (0 weeks), after 4 weeks of use, after 8 weeks of use, and after 12 weeks of use, visual evaluation, measurement using the device (photographing, skin wrinkles, and skin firmness measurement) were performed. And safety assessment to assess the effectiveness of creams containing wheat germ extracts on improving skin wrinkles in humans. The specific information and methods of use of the samples are summarized in Tables 5 and 6 below.

The subject of clinical evaluation, in order to stabilize the skin after washing, to maintain a fixed temperature and humidity without air flow and direct sunlight Conditions (22 ± 2 ° C, 50 ± 5%) rest for 20 minutes, then participate in various measurements and assessments; the results and evaluation steps are summarized in Table 7 below.

Regarding the measurement using the device, the skin firmness of the left and right cheeks of the subject was measured for clinical evaluation before use (0 weeks), after 4 weeks of use, after 8 weeks of use, and after 12 weeks of use.

1-2-2: Comparative evaluation of control creams

Measurement of wrinkles around the eyes (replica)

Skin-Visiometer® SV600 (Courage+Khazaka GmbH, Germany) is a device for measuring the degree of improvement of skin wrinkles by analyzing the light intensity generated when light emitted from an artificial light source penetrates the resin material. The analysis was performed using a Visiometer (image analyzer software) after inserting the prepared skin replica into the analysis kit in the device. A decrease in the R1 and R3 values indicates an improvement in skin wrinkles, and thus the wrinkle depth is reduced, and the unit used is Italian unit (AU). As shown in Fig. 7, the wrinkle parameter (roughness parameter, R parameter) R1 (skin roughness) indicates the distance between the highest and lowest points through the skin roughness profile, and R3 (average roughness) indicates continuous division into 5 The arithmetic mean of the values of the R1 values of the divided regions in the cross-sectional view after the equal length.

The measurement results are shown in Table 8 below. When using CJD cream, the R1 and R3 values were displayed at all time points (after 4 weeks, after 8 weeks, and after 12 weeks) compared to those before using CJD cream. Significantly a statistically significant reduction compared to the control cream showed a significant effect in improving wrinkles.

Comparing results, as shown in Table 9 and Figures 8a to 8c, the values of skin roughness (R1) and average roughness (R3) were used in the CJD cream group compared to the control cream group. There was a statistically significant decrease in the time point after 8 weeks (p<0.05).

Measurement of skin firmness

DermaScanC ^® USB is a 20MHz high-resolution ultrasonic imaging device, which is used to generate ultrasonic waves of various sizes and echoes between different intensity tissues to make changes in the skin (due to changes in the cortex due to collagen fiber reflectance, etc.) ) Imaging device. The size of the echo is synthesized by computer to represent the color, resulting in a two-dimensional image. In this test, the skin firmness of the left and right sides of the face of the subject to be studied (the area where the lower part of the corner of the eye is in contact with the nasal end side) was measured. The intensity value is analyzed from the captured image.

The skin strength was statistically significantly increased (p < 0.05) at the time point after 12 weeks of use of the CJD cream group as compared to before the use of the cream (Table 10 and Figures 8d to 8f).

When compared between groups, the CJD cream group showed a statistically significant increase (improvement) in skin intensity at 12 o'clock after the cream was used ( p < 0.05) compared with the control cream group (Table 11 and Figures 8d and 8f).

Safety assessment

After 4, 8, and 12 weeks of use of the test product (CJD cream and control cream), the skin condition of the clinical evaluation subject was observed, and the skin condition of the subjective and objective stimuli was confirmed by the question and answer with the clinical evaluation subject. And record and evaluate the results. The results confirmed that no adverse reactions occurred in all subjects for clinical evaluation (Table 12).

Using SPSS ^® Kit Version program 22 via the evaluation results obtained using the apparatus of statistical analysis. The Shapiro-Wilk assay was used to confirm the normality of the measurements obtained prior to use of the test product; and the paired t-test was used to confirm the homogeneity of the measurements obtained prior to the use of the test product between the groups. Regarding the comparison before and after the test product is used, when the measured value conforms to the normal distribution, the statistical significance is confirmed by repeated measurement ANOVA; when the measured value does not conform to the normal distribution, the non-parametric test is used (Kruskal-Wallis and Mann-Whitney U test) Confirm statistical significance. Regarding the comparison between the groups, statistical significance was confirmed using repeated measures ANOVA, taking into account the interaction between the results of repeated measurements by the same subject, and the significance level was set at p < 0.05. Frequency analysis was used to analyze the questionnaire.

Based on the results of the clinical evaluation, no adverse skin reactions were observed in all subjects for clinical evaluation, and CJD cream exhibited a significant wrinkle improvement effect compared to the control cream.

1-2-3: Evaluation of ADE Cream

Measurement of wrinkles around the eyes (replica)

The measurement was carried out in the same manner as in 1-2-2. As a result, the skin roughness (R1) was statistically significantly reduced after 8 weeks of use of the CJD cream, respectively, and the skin roughness (R1) and the average roughness were 12 weeks after the use of the CJD cream, respectively, compared to the use of the CJD cream. Degree (R3) was statistically significantly reduced (improved) (p < 0.05) (Table 13 and Figures 9a to 9c below). These improvements show superiority over ADE creams.

The variation of the R parameters according to the time points between the groups is shown in Table 14 below. The extract of the wheat germ fermentation product is a natural extract, However, it has the effect of being equivalent to the adenosine-containing ADE cream obtained by chemical purification procedures (resin adsorption, ammonia water and ethanol elution, etc.) after microbial fermentation.

Measurement of skin firmness

The measurement was carried out in the same manner as in 1-2-2. As a result, the skin thickness (distance) was statistically significantly increased after 8 weeks and 12 weeks of use of the CJD cream before the use of the CJD cream, and the skin density (strength) was counted after 12 weeks of using the CJD cream. Significantly increased (improved) (p < 0.05) (Figures 15 and 9d to 9f below). These improvements show an equivalent or superior to ADE cream.

The skin tightness changes between groups according to time points are shown in Table 16 below. As mentioned above, although the extract of wheat germ fermentation product is It is a natural extract, but it is shown to have an effect equivalent to the adenosine-containing ADE cream obtained through a chemical purification procedure.

Safety assessment

After 4, 8, and 12 weeks of use of the test product (CJD cream and ADE cream), the skin condition of the clinical evaluation subject was observed, and the skin condition of subjective and objective stimulation was confirmed and recorded by the question and answer with the subject. And the results of the assessment. The results confirmed that no adverse reactions occurred in all subjects for clinical evaluation (Table 17).

Based on the results of the above clinical evaluation, no adverse skin reactions were observed in all clinically evaluated subjects, and CJD cream exhibited the same wrinkle-reducing effect as ADE cream.

In view of the above, it should be understood by those skilled in the art that the present disclosure can be implemented in other specific forms without modifying the technical concept or essential features of the present disclosure. In this regard, the specific examples disclosed herein are for illustrative purposes only and should not be construed as limiting the scope of the disclosure. Rather, the invention is not intended to be limited to the exemplification of the invention, but the various alternatives, modifications, equivalents, and other elements within the spirit and scope of the disclosure as defined by the scope of the appended claims. Body instance.

Since the figure in this case is the result data of the test compound, it is not a representative figure of this case. Therefore, there is no designated representative map in this case.

Claims (12)

A cosmetic composition for preventing or ameliorating skin wrinkles, comprising a compound of the following formula 1, or a wheat germ fermentation product or an extract thereof: The cosmetic composition according to claim 1, wherein the wheat germ fermentation product or the extract thereof comprises the compound of the above formula 1. The cosmetic composition according to claim 1, wherein the fermentation product of the wheat germ is obtained by inoculating yeast to a wheat germ or a medium containing wheat germ, followed by culturing. The cosmetic composition according to claim 3, wherein the yeast is Saccharomyces cerevisiae . The cosmetic composition according to claim 3, wherein the culture is carried out at 20 ° C to 40 ° C for 12 hours to 60 hours. The cosmetic composition according to claim 1, wherein the wheat germ fermentation product or the extract thereof is contained in an amount of from 0.001% by weight to 10% by weight based on the total weight of the cosmetic composition. The cosmetic composition according to claim 1, wherein the composition promotes biosynthesis of collagen. The cosmetic composition according to claim 1, wherein the composition inhibits the expression of MMP-1 induced by UV irradiation. The cosmetic composition according to claim 1, wherein the The composition inhibits the activity of elastase. The cosmetic composition of claim 1, wherein the composition enhances skin firmness of the skin. A pharmaceutical composition for preventing or treating skin wrinkles, comprising a compound of the following formula 1, or a wheat germ fermentation product or an extract thereof: A quasi-drug composition for preventing or ameliorating skin wrinkles, comprising a compound of the following formula 1, or a wheat germ fermentation product or an extract thereof: